541-549DOI: 10.17235/reed.2016.4440/2016
Sabino Riestra, Ruth de Francisco, Miguel Arias-Guillén, Cristina Saro, María García-Alvarado, José María Duque, Juan José Palacios, Fernando Muñoz, Lorena Blanco, Olegario Castaño, Isabel Pérez-Martínez, Pablo Martínez-Camblor, Dolores Pérez Hernández, Adolfo Suárez,
Abstract
Aims: To determine risk factors for active tuberculosis in patients with inflammatory bowel diseases.
Methods: Retrospective, case-control study at 4 referral hospitals in Spain. Cases developed tuberculosis after a diagnosis of inflammatory bowel disease. Controls were inflammatory bowel disease patients who did not develop tuberculosis. For each case, we randomly selected 3 controls matched for sex, age (within 5 years) and time of inflammatory bowel disease diagnosis (within 3 years). Inflammatory bowel disease characteristics, candidate risk factors for tuberculosis and information about the tuberculosis episode were recorded. Multivariate analysis and a Chi-squared automatic interaction detector were used.
Results: Thirty-four cases and 102 controls were included. Nine of the 34 cases developed active tuberculosis between 1989 and 1999, and 25 became ill between 2000 and 2012. Multivariate regression showed an association between active tuberculosis and anti-TNF (tumor necrosis factor) therapy in the previous 12 months (OR 7.45; 95% CI, 2.39-23.12; p = .001); hospitalization in the previous 6 months (OR 4.38; 95% CI, 1.18-16.20; p = .027); and albumin levels (OR 0.88; 95% CI, 0.81-0.95; p = .001). The median time between the start of biologic therapy and the onset of active tuberculosis was 13 (interquartile range, 1-58) months. Tuberculosis developed after a year of anti-TNF therapy in 53%, and late reactivation occurred in at least 3 of 8 patients.
Conclusions: The main risks factors for developing tuberculosis were anti-TNF therapy and hospitalization. Over half the cases related to anti-TNF treatment occurred after a year.
New comment
Comments
No comments for this article
References
1. Rahier JF, Magro F, Abreu C et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2014; 8:443-68. DOI: 10.1016/j.crohns. 2013. 12. 013
2. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001; 345: 1098-104. DOI: 10.1056/NEJMoa011110
3. Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52:1766-72. DOI: 10.1002/art.21043
4. Mañosa M, Domènech E, Cabré E. Current incidence of active tuberculosis in IBD patients treated with anti-TNF agents: still room for improvement. J Crohns Colitis 2013; 7:499-500. DOI: 10.1016/j.crohns.2013.04.021
5. Gómez-Reino JJ, Carmona L, Angel Descalzo M et al. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007; 57:756-61. DOI: 10.1002/art.22768
6. Jáuregui-Amezaga A, Turon F, Ordás I et al. Risk of developing tuberculosis under antiTNF treatment despite latent infection screening. J Crohns Colitis 2013; 7:208-12. DOI: 10.1016/j.crohns. 2012.05.012
7. Aberra FN, Stettler N, Brensinger C et al. Risk for Active Tuberculosis in Inflammatory Bowel Disease Patients. Clin Gastroenterol Hepatol 2007; 5: 1070-5. DOI: 10.1016/j.cgh.2007.04.007
8. Marehbian J, Arrighi HM, Hass S et al. Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease. Am J Gastroenterol 2009 104:2524-33. DOI: 10.1038/ajg.2009.322
9. Satsangi J, Silverberg MS, Vermeire S et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749–53. DOI:10.1136/ gut.2005.082909
10 Obrador A, López San Román A, Muñoz P et al. Guía de consenso sobre tuberculosis y tratamiento de la enfermedad inflamatoria intestinal con infliximab. Grupo Español de Trabajo de Enfermedad de Crohn y Colitis Ulcerosa (GETECCU). Gastroenterol Hepatol 2003; 26: 29-33. DOI: 10.1016/S0210-5705(03)70338-0
11 Kamerbeek J, Schouls L, Kolk A et al. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol 1997; 35:907-14.
12 van Embden JD, Cave MD, Crawford JT et al. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol 1993; 31: 406–9.
13 Kass G. An exploratory technique for investigating large quantities of categorical data. Applied Statistics 1980; 29: 119–27. DOI:10.2307/2986296
14 Casas-Fischer R, Penedo-Pallares A, Palacios-Gutiérrez JJ et al. Outbreak or coincidental cases of tuberculosis? Genotyping provides the clue. Am J Infect Control 2012;40:9-10. DOI: 10.1016/j.ajic.2011.03.003
15 Centro Nacional de Epidemiología. Instituto de Salud Carlos III. Informe epidemiológico sobre la situación de la tuberculosis en España. 2014. Madrid, 2015. Available from: URL: http://www.isciii.es/ISCIII/ es/ contenidos/fd-servicios-cientifico-tecnicos/fd-vigilancias-alertas/fd-enfermedades/pdf_2015/TB_Informe_2014.pdf
16 Arias-Guillén M, Riestra S, de Francisco R et al. T-cell profiling and the immunodiagnosis of latent tuberculosis infection in patients with inflammatory bowel disease. Inflamm Bowel Dis 2014;20:329-38. DOI: 10.1097/01.MIB.0000438429. 38423.62
17 Zabana Y, Domènech E, San Román AL et al. Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy. Inflamm Bowel Dis 2008; 14:1387-91 DOI:10.1002/ibd.20496
18 Jick SS, Lieberman ES, Rahman MU et al. Glucocorticoid Use, Other Associated Factors, and the Risk of Tuberculosis. Arthritis Rheum 2006;55:19-26. DOI: 10.1002/art.21705
19 Deepak P, Stobaugh DJ, Ehrenpreis ED. Infectious complications of TNF-inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting System. J Gastrointestin Liver Dis 2013; 22: 269-76.
20 Lorenzetti R, Zullo A, Ridola L et al. Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials. Ann Med 2014; 46: 547–54. DOI:10.3109/07853890.2014.941919
21 Ford AC, Peyrin-Biroulet L Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol 2013;108:1268-76. DOI: 10.1038/ajg.2013.138
22 Colombel JF, Loftus Jr EV, Tremaine WJ et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004; 126:19–31. DOI: 10.1053/ j.gastro. 2003.10.047
23 Fidder H, Schnitzler F, Ferrante M et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009; 58:501–8. DOI: 10.1136/ gut.2008.163642.
24 Vaughn BP, Doherty GA, Gautam S et al. Screening for Tuberculosis and Hepatitis B prior to the initiation of anti-tumor necrosis therapy. Inflamm Bowel Dis 2012;18:1057–63. DOI: 10.1002/ibd.21824
25 Mow WS, Abreu-Martin MT, Papadakis KA et al. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol 2004; 2: 309-13. DOI: 10.1016/S1542-3565(04)00060-6
26 Smith MY, Attig B, McNamee L et al. Tuberculosis screening in prescribers of anti-tumor necrosis factor therapy in the European Union. Int J Tuberc Lung Dis 2012; 16:1168-73. DOI: 10.5588/ijtld.12.0029
27 Pearson ML, Jereb JA, Frieden TR et al. Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis. A risk to patients and health care workers. Ann Intern Med 1992; 117: 191-6. DOI: 10.7326/0003-4819-117-3-191
28 Harris TG, Sullivan Meissner J et al. Delay in diagnosis leading to nosocomial transmission of tuberculosis at a New York City health care facility. Am J Infect Control 2013;41:155-60. DOI:10.1016 /j.ajic.2012.02.015.